Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05257967

CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease

Led by British Columbia Cancer Agency · Updated on 2025-02-11

10

Participants Needed

1

Research Sites

232 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Leptomeningeal disease is malignant seeding of the leptomeninges and presents with a variety of symptoms frequently impacting quality of life. With improvement in treatment options, rates of leptomeningeal disease are increasing and currently found in up to 9% of EGFR mutant NSCLC. Systemic therapy may be more effective if it can target the correct molecular aberration. The molecular characterization of central nervous system disease may differ from disease outside of the central nervous system. The aim of this pilot trial is to evaluate for molecular differences between cerebral spinal fluid (CSF) and blood circulating tumor DNA (ctDNA) through the use of ddPCR and BC Cancer NGS panel molecular testing.

CONDITIONS

Official Title

CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older at the time of informed consent
  • Histologically or cytologically confirmed metastatic EGFR mutant non-small cell lung cancer
  • Leptomeningeal disease confirmed by brain MRI or cerebrospinal fluid cytology
  • ECOG performance status of 0 to 3
  • Life expectancy of at least 8 weeks
  • Adequate blood counts and organ function for testing
  • Ability to give informed consent for study procedures
Not Eligible

You will not qualify if you...

  • Unable to undergo lumbar puncture due to low platelets, bleeding disorders, or inability to cooperate or consent
  • Considered unfit by treating clinician to participate
  • Spinal leptomeningeal disease seen on MRI spine that prevents safe lumbar puncture

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

BC Cancer

Vancouver, British Columbia, Canada, V5Z4E6

Actively Recruiting

Loading map...

Research Team

C

Cheryl Ho, MD

CONTACT

B

Barbara Melosky, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here